A Curve‐Free Method for Phase I Clinical Trials (Q4667490): Difference between revisions
From MaRDI portal
ReferenceBot (talk | contribs) Changed an Item |
Normalize DOI. |
||
| (One intermediate revision by one other user not shown) | |||
| Property / DOI | |||
| Property / DOI: 10.1111/j.0006-341X.2000.00609.x / rank | |||
| Property / full work available at URL | |||
| Property / full work available at URL: https://doi.org/10.1111/j.0006-341x.2000.00609.x / rank | |||
Normal rank | |||
| Property / OpenAlex ID | |||
| Property / OpenAlex ID: W2080277472 / rank | |||
Normal rank | |||
| Property / DOI | |||
| Property / DOI: 10.1111/J.0006-341X.2000.00609.X / rank | |||
Normal rank | |||
Latest revision as of 15:00, 30 December 2024
scientific article; zbMATH DE number 2159529
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | A Curve‐Free Method for Phase I Clinical Trials |
scientific article; zbMATH DE number 2159529 |
Statements
A Curve‐Free Method for Phase I Clinical Trials (English)
0 references
20 April 2005
0 references
continual reassessment method
0 references
dose-finding studies
0 references
maximum tolerated dose
0 references
neutral to the right process
0 references
phase I clinical trial
0 references
product-of-beta priors
0 references
toxicity
0 references
0 references
